Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de 104 semanas de cápsulas orales de ritlecitinib en adultos con vitíligo no segmentario (activo y estable) Tranquillo 2 (Tranquillo 2)

9 de noviembre de 2026 actualizado por: Pfizer

Un estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo de 52 semanas con un período de extensión doble ciego de 52 semanas con titulación aleatoria de aumento o reducción de dosis que investiga la eficacia, seguridad y tolerabilidad de ritlecitinib en participantes adultos Con vitíligo no segmentario

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo. Vitiligo causes white patches on your skin when the cells that give your skin color are destroyed. Nonsegmental means that it can affect both sides of the body such as both knees and both hands.

Ritlecitinib has been tested in earlier clinical studies and has a favorable safety profile. At present there are no approved medications taken by mouth to treat nonsegmental vitiligo.

This study is seeking participants who:

  • Are 18 years of age or older.
  • are confirmed to have nonsegmental vitiligo for at least 3 months.
  • Are willing to stop all other treatments that they may be taking for vitiligo.

In this study participants will be chosen by chance, like drawing names out of a hat to receive 1 of 3 treatments:

•Part I where two different amounts of ritlecitinib (50 mg and 100 mg) are taken once daily. It will be compared to placebo. Placebo is a dummy capsule. It doesn't have any medicine used in the study.

Participants receiving placebo who have not responded to treatment after 52 weeks will be given 100 milligrams or 50 milligrams of ritlecitinib for the remaining 52 weeks of the study.

• In Part II, participants will only receive 100 milligrams of ritlecitinib. About 1000 participants will take part in Part I and around 450 in Part II globally. The study will compare the experiences of people receiving ritlecitinib to those of the people who do not. This will help see if ritlecitinib is safe and effective.

People in Part I will be in this study for about 26 months and people in Part II will be in this study for about 14 months. During the study, participants in part I will need to visit the study site at least 17 times. In part II, participants will visit at least 11 times.

Participants will undergo various tests and procedures such as:

  • vitiligo rating,
  • physical examinations,
  • hearing tests,
  • blood tests,
  • x-ray,
  • ECG,
  • photographs of areas with vitiligo. Participants will be asked to complete questionnaires about their vitiligo.

Descripción general del estudio

Descripción detallada

Study B7981080 is a Phase 3 randomized, double-blind, multicenter study with a 52-week placebo-controlled period (Part Ia) followed by a double-blind 52-week extension period (Part Ib) that includes randomized dose-up/down titration and a de novo 52-week non-randomized open-label cohort (Part II), investigating the efficacy, safety, and tolerability of ritlecitinib 100 mg QD and 50 mg QD compared with placebo in adult participants with nonsegmental active or stable vitiligo

Tipo de estudio

Intervencionista

Inscripción (Actual)

1571

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Dresden, Alemania, 01307
        • Universitaetsklinikum Carl Gustav Carus Dresden
    • Hesse
      • Darmstadt, Hesse, Alemania, 64283
        • Rosenpark Research GmbH
    • North Rhine-Westphalia
      • Bielefeld, North Rhine-Westphalia, Alemania, 33647
        • Klinikum Bielefeld Rosenhöhe
      • Bielefeld, North Rhine-Westphalia, Alemania, 33647
        • Klinikum Bielefeld gem. GmbH
      • Bochum, North Rhine-Westphalia, Alemania, 44793
        • Hautzentrum im Jahrhunderthaus
      • Bonn, North Rhine-Westphalia, Alemania, 53127
        • Universitätsklinikum Bonn
    • Rhineland-Palatinate
      • Mainz, Rhineland-Palatinate, Alemania, 55128
        • BAG Drs. Med. Quist PartG
    • Saxony
      • Dresden, Saxony, Alemania, 01097
        • Hautarztpraxis Dr. Beatrice Gerlach
      • Leipzig, Saxony, Alemania, 04207
        • Hautarztpraxis Dr. Neubauer
    • Saxony-Anhalt
      • Magdeburg, Saxony-Anhalt, Alemania, 39104
        • HNO-Praxis Dr. Kugler in Magdeburg
      • Magdeburg, Saxony-Anhalt, Alemania, 39104
        • Magdeburger Company for Medical Studies and Services
      • Magdeburg, Saxony-Anhalt, Alemania, 39104
        • Radiologie Ulrichshaus
    • Australian Capital Territory
      • Phillip, Australian Capital Territory, Australia, 2606
        • Paratus Clinical Research Woden
    • New South Wales
      • Kogarah, New South Wales, Australia, 2217
        • St George Dermatology & Skin Cancer Centre
      • St Leonards, New South Wales, Australia, 2065
        • Royal North Shore Hospital
    • Queensland
      • Greenslopes, Queensland, Australia, 4120
        • Veracity Clinical Research
    • South Australia
      • Campbelltown, South Australia, Australia, 5074
        • North Eastern Health Specialists
      • Woodville South, South Australia, Australia, 5011
        • The Queen Elizabeth Hospital
    • Victoria
      • East Melbourne, Victoria, Australia, 3002
        • Dr Rodney Sinclair Pty Ltd
      • Melbourne, Victoria, Australia, 3004
        • The Alfred Hospital
      • Mitcham, Victoria, Australia, 3132
        • Institute for Skin, Health and Immunity
      • Parkville, Victoria, Australia, 3050
        • The Royal Melbourne Hospital
    • Western Australia
      • Fremantle, Western Australia, Australia, 6160
        • Fremantle Dermatology
      • Sofia, Bulgaria, 1202
        • Diagnostic Consultative Center "Ascendent"
    • Pazardzhik
      • Pazardzhik, Pazardzhik, Bulgaria, 4400
        • MHAT Pazardzhik
    • Pernik
      • Pernik, Pernik, Bulgaria, 2300
        • Diagnostic Consultative Center 1 - Pernik
    • Pleven
      • Pleven, Pleven, Bulgaria, 5800
        • Medical Center Exacta Medica
    • Ruse
      • Rousse, Ruse, Bulgaria, 7000
        • Medical Center Prolet EOOD
    • Sofia
      • Sofia, Sofia, Bulgaria, 1528
        • Diagnostic - Consultative Center XXVIII - Sofia
      • Sofia, Sofia, Bulgaria, 1618
        • "Diagnostic - Consultative Center XX - Sofia" EOOD
    • Sofia (stolitsa)
      • Sofia, Sofia (stolitsa), Bulgaria, 1431
        • Diagnostic Consultative Center Aleksandrovska
      • Sofia, Sofia (stolitsa), Bulgaria, 1407
        • ASMC - IPSMC - skin and venereal diseases
      • Sofia, Sofia (stolitsa), Bulgaria, 1463
        • Diagnostic Consultative Centre (DCC) - Foкus 5
      • Sofia, Sofia (stolitsa), Bulgaria, 1606
        • Clinic EvroDerma
    • Stara Zagora
      • Stara Zagora, Stara Zagora, Bulgaria, 6003
        • UMHAT "Prof. Dr. Stoyan Kirkovich"AD
    • Veliko Tarnovo
      • Veliko Tarnovo, Veliko Tarnovo, Bulgaria, 5000
        • Center for Skin and Venereal Diseases - Veliko Tarnovo
    • Yambol
      • Yambol, Yambol, Bulgaria, 8600
        • Multiprofile Hospital for Active Treatment Sv. Panteleymon - Yambol AD
    • Bruxelles-capitale, Région de
      • Brussels, Bruxelles-capitale, Région de, Bélgica, 1070
        • Université Libre de Bruxelles - Hôpital Erasme
      • Brussels, Bruxelles-capitale, Région de, Bélgica, 1200
        • Cliniques universitaires Saint-Luc
    • LIÈGE
      • Liège, LIÈGE, Bélgica, 4000
        • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
    • OOST-VLAANDEREN
      • Ghent, OOST-VLAANDEREN, Bélgica, 9000
        • UZ Gent
    • VLAAMS-BRABANT
      • Leuven, VLAAMS-BRABANT, Bélgica, 3000
        • UZ Leuven
    • Alberta
      • Calgary, Alberta, Canadá, T2J 7E1
        • Dermatology Research Institute
      • Edmonton, Alberta, Canadá, T6G 1C3
        • Alberta Dermasurgery Centre
    • British Columbia
      • Vancouver, British Columbia, Canadá, V5Z 4E8
        • The Skin Care Centre
    • Manitoba
      • Winnipeg, Manitoba, Canadá, R3M 3Z4
        • Wiseman Dermatology Research Inc.
    • Ontario
      • Barrie, Ontario, Canadá, L4M 7G1
        • SimcoDerm Medical and Surgical Dermatology Center
      • Greater Sudbury, Ontario, Canadá, P3C 1X3
        • Medicor Research Inc
      • Greater Sudbury, Ontario, Canadá, P3C 1X8
        • Sudbury Skin Clinique
      • London, Ontario, Canadá, N6H 5L5
        • DermEffects
      • Mississauga, Ontario, Canadá, L4Y 4C5
        • DermEdge Research
      • Oakville, Ontario, Canadá, L6J 7W5
        • The Centre for Clinical Trials
      • Ottawa, Ontario, Canadá, K1K 4L2
        • JRB Research Inc.
      • Richmond Hill, Ontario, Canadá, L4B 1L1
        • York Dermatology Clinic & Research Centre
      • Toronto, Ontario, Canadá, M2N 3A6
        • North York Research Inc
      • Toronto, Ontario, Canadá, M4W 2N4
        • Dermatology on Bloor - Research Toronto
    • Quebec
      • Montreal, Quebec, Canadá, H2X 2V1
        • Innovaderm Research Inc.
      • Montreal, Quebec, Canadá, H1Y 3L1
        • Centre de Recherche Saint-Louis (Montréal)
      • Québec, Quebec, Canadá, G2J 0C4
        • Alpha Recherche Clinique
      • Québec, Quebec, Canadá, G1V 4X7
        • Centre de Recherche Dermatologique du Quebec metropolitain
      • Québec, Quebec, Canadá, G1V 4T3
        • Diex Recherche Quebec
      • Sherbrooke, Quebec, Canadá, J1L 0H8
        • Diex Recherche Sherbrooke
      • Sherbrooke, Quebec, Canadá, J1G 1X9
        • Centre de Recherche Saint-Louis
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canadá, S7K 2C1
        • Skinsense Medical Research
      • Saskatoon, Saskatchewan, Canadá, S7T 0G3
        • Saskatoon Dermatology Centre
      • Bratislava, Eslovaquia, 851 01
        • Derma therapy spol. s.r.o.
      • Bratislava, Eslovaquia, 841 02
        • BeneDerma
      • Bratislava, Eslovaquia, 811 09
        • CLINIQ s.r.o.
      • Košice, Eslovaquia, 040 23
        • Poliklinika ProCare Kosice s.r.o.
      • Košice, Eslovaquia, 04001
        • Topskin pro s.r.o.
    • Banská Bystrica Region
      • Banská Bystrica, Banská Bystrica Region, Eslovaquia, 97517
        • Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica
    • Presov
      • Svidník, Presov, Eslovaquia, 089 01
        • SANARE, s.r.o
    • Trnava Region
      • Trnava, Trnava Region, Eslovaquia, 917 02
        • Fakultna nemocnica Trnava
      • Santiago de Compostela, España, 15702
        • Clínica Gaias - Santiago
    • Andalusia
      • Córdoba, Andalusia, España, 14004
        • Hospital Universitario Reina Sofia
      • Córdoba, Andalusia, España, 14001
        • AUDIKA
    • BARCELONA
      • Barcelona, BARCELONA, España, 08041
        • Hospital de la Santa Creu i Sant Pau
    • Barcelona [barcelona]
      • Badalona, Barcelona [barcelona], España, 08916
        • Hospital Germans Trias i Pujol
      • L'Hospitalet de Llobregat, Barcelona [barcelona], España, 08907
        • Hospital Universitari de Bellvitge
    • Galicia [galicia]
      • Santiago de Compostela, Galicia [galicia], España, 15702
        • Clínica Gaias - Santiago
    • Madrid
      • Madrid, Madrid, España, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Madrid, España, 28027
        • Clinica Universidad de Navarra
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, España, 28031
        • Hospital Universitario Infanta Leonor
    • VALÈNCIA
      • Valencia, VALÈNCIA, España, 46026
        • Hospital Universitari i Politecnic La Fe
    • ZARAGOZA
      • Zaragoza, ZARAGOZA, España, 50009
        • Hospital Universitario Miguel Servet
    • Arizona
      • Scottsdale, Arizona, Estados Unidos, 85260
        • Center for Dermatology and Plastic Surgery/CCT Research
    • Arkansas
      • Bryant, Arkansas, Estados Unidos, 72022
        • Dermatology Trial Associates
    • California
      • Fountain Valley, California, Estados Unidos, 92708
        • First OC Dermatology Research Inc
      • Huntington Beach, California, Estados Unidos, 92648
        • Seaside Audiology Vertigo & Ear Specialists
      • Los Angeles, California, Estados Unidos, 90056
        • Wallace Medical Group, Inc
      • Oakland, California, Estados Unidos, 94611
        • Kaiser Permanente
      • Oxnard, California, Estados Unidos, 93030
        • Cura Clinical Research - Oxnard
      • Rancho Santa Margarita, California, Estados Unidos, 92688
        • Mission Dermatology Center
      • Rolling Hills Estates, California, Estados Unidos, 90274
        • Peninsula Research Associates
      • Sacramento, California, Estados Unidos, 95815
        • Integrative Skin Science and Research
      • San Diego, California, Estados Unidos, 92122
        • University of California San Diego - La Jolla
      • Santa Ana, California, Estados Unidos, 92706
        • Wolverine Clinical Trials
    • Florida
      • Boynton Beach, Florida, Estados Unidos, 33436
        • Encore Medical Research of Boynton Beach
      • Fort Lauderdale, Florida, Estados Unidos, 33308
        • FXM Clinical Research - Fort Lauderdale
      • Hialeah, Florida, Estados Unidos, 33012
        • Direct Helpers Research Center
      • Miami, Florida, Estados Unidos, 33136
        • University of Miami
      • Miami, Florida, Estados Unidos, 33165
        • New Horizon Research Center
      • Miami, Florida, Estados Unidos, 33136
        • SouthCoast Research Center
      • Miami, Florida, Estados Unidos, 33173
        • Well Pharma Medical Research, Corp.
      • Miami, Florida, Estados Unidos, 33173
        • Skin Research of South Florida
      • Miami, Florida, Estados Unidos, 33144
        • Bio-Medical Research LLC
      • Miami, Florida, Estados Unidos, 33126
        • Clever Medical Research
      • Miami, Florida, Estados Unidos, 33133
        • Miami Dermatology and Laser Research
      • Miami, Florida, Estados Unidos, 33175
        • FXM Clinical Research - Miami
      • Miami, Florida, Estados Unidos, 33176
        • Health and Life Research Institute
      • Miami, Florida, Estados Unidos, 33176
        • University of Miami, Kendall Office
      • Miami, Florida, Estados Unidos, 33179
        • Floridian Research Institute Llc
      • Miami, Florida, Estados Unidos, 33186
        • Sanitas Research
      • Miami, Florida, Estados Unidos, 33136
        • University of Miami Dermatology Clinical Trials Unit
      • Miami Lakes, Florida, Estados Unidos, 33016
        • Wellness Clinical Research, LLC
      • Miramar, Florida, Estados Unidos, 33027
        • FXM Clinical Research Miramar, LLC
      • St. Petersburg, Florida, Estados Unidos, 33714
        • GCP Research, Global Clinical professionals
      • Tampa, Florida, Estados Unidos, 33607
        • Advanced Clinical Research Institute
      • Tampa, Florida, Estados Unidos, 33612
        • USF Health
    • Georgia
      • Savannah, Georgia, Estados Unidos, 31419
        • Sidney P. Smith, MD, PC dba Georgia Skin & Cancer Clinic
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60625
        • Endeavor Health Audiology -CHICAGO
      • Lake Bluff, Illinois, Estados Unidos, 60044
        • Endeavor Health Audiology -LAKE BLUFF
      • Northbrook, Illinois, Estados Unidos, 60062
        • Endeavor Health Audiology-NORTHBROOK
      • Skokie, Illinois, Estados Unidos, 60076
        • Endeavor Health Audiology-SKOKIE
      • Skokie, Illinois, Estados Unidos, 60077
        • Endeavor Health-Dermatology Clinical Trials Unit
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46250
        • Dawes Fretzin Clinical Research Group, LLC
      • South Bend, Indiana, Estados Unidos, 46617
        • The South Bend Clinic, LLC
    • Maryland
      • Rockville, Maryland, Estados Unidos, 20850
        • Dermatology and Skin Cancer Specialists, LLC
    • Michigan
      • Auburn Hills, Michigan, Estados Unidos, 48326
        • Oakland Hills Dermatology
      • Detroit, Michigan, Estados Unidos, 48202
        • Henry Ford Medical Center - New Center One
      • Detroit, Michigan, Estados Unidos, 48201
        • Wayne Health
      • Detroit, Michigan, Estados Unidos, 48201
        • CS Mott Center
    • Missouri
      • Saint Joseph, Missouri, Estados Unidos, 64506
        • MediSearch Clinical Trials
    • Nebraska
      • Lincoln, Nebraska, Estados Unidos, 68516
        • Physician Research Collaboration, LLC
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87102
        • University of New Mexico Health Sciences Center
    • New York
      • New York, New York, Estados Unidos, 10128
        • OptiSkin Medical
      • Stony Brook, New York, Estados Unidos, 11790
        • DermResearchCenter of New York, Inc.
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28277
        • Darst Dermatology
      • Charlotte, North Carolina, Estados Unidos, 28211
        • DJL Clinical Research, PLLC
    • Ohio
      • Bexley, Ohio, Estados Unidos, 43209
        • Bexley Dermatology Research
      • Columbus, Ohio, Estados Unidos, 43213
        • Centricity Research Columbus Ohio Multispecialty
    • Oregon
      • Portland, Oregon, Estados Unidos, 97210
        • Oregon Dermatology and Research Center
    • Pennsylvania
      • Plymouth Meeting, Pennsylvania, Estados Unidos, 19462
        • Dermatology Associates of Plymouth Meeting
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Medical University of South Carolina
      • Columbia, South Carolina, Estados Unidos, 29212
        • Columbia Dermatology & Aesthetics
      • Greenville, South Carolina, Estados Unidos, 29615
        • Palmetto Clinical Trial Services, LLC
    • Texas
      • Houston, Texas, Estados Unidos, 77004
        • Center for Clinical Studies
      • Pflugerville, Texas, Estados Unidos, 78660
        • Austin Institute for Clinical Research
      • Sugar Land, Texas, Estados Unidos, 77479
        • Complete Dermatology
      • The Woodlands, Texas, Estados Unidos, 77380
        • The Woodlands Dermatology Associates, PA
    • Utah
      • Murray, Utah, Estados Unidos, 84107
        • University of Utah
      • Springville, Utah, Estados Unidos, 84663
        • Springville Dermatology - Springville/CCT Research
    • Virginia
      • Forest, Virginia, Estados Unidos, 24551
        • Eurofins Cosmetics CRL LLC
      • Debrecen, Hungría, 4031
        • DERMA-B Egészségügyi és Szolgáltató
      • Kaposvár, Hungría, 7400
        • Derm-Surg Egészségügyi Szolgáltató és Tanácsadó Kft.
    • Baranya
      • Pécs, Baranya, Hungría, 7632
        • Pécsi Tudományegyetem Klinikai Központ
    • Budapest
      • Budapest, Budapest, Hungría, 1036
        • Óbudai Egészségügyi Centrum
    • Békéscsaba
      • Békéscsaba, Békéscsaba, Hungría, 5600
        • Trial Pharma - Semper Medical Center
    • Csongrád megye
      • Szeged, Csongrád megye, Hungría, 6720
        • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
    • Debrecen
      • Debrecen, Debrecen, Hungría, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Debrecen, Debrecen, Hungría, 4027
        • Orvostudomanyi Kutato es Fejleszto Kft
    • Abruzzo
      • L’Aquila, Abruzzo, Italia, 67100
        • ASL1 Avezzano-Sulmona-L'Aquila
    • CAGLIARI
      • Cagliari, CAGLIARI, Italia, 09124
        • Ospedale Civile - Azienda Ospedaliera Universitaria di Cagliari
    • FIRENZE
      • Florence, FIRENZE, Italia, 50125
        • Presidio Ospedaliero Firenze Centro Piero Palagi
    • Lombardy
      • Milan, Lombardy, Italia, 20122
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    • RM
      • Roma, RM, Italia, 00144
        • IRCCS Istituti Fisioterapici Ospitalieri
    • ROMA
      • Rome, ROMA, Italia, 00148
        • Ospedale Israelitico
      • Rome, ROMA, Italia, 00167
        • Istituto Dermopatico Immacolata
    • Aichi-ken
      • Nagoya, Aichi-ken, Japón, 457-8510
        • Japan Community Health Care Organization Chukyo Hospital
    • Chiba
      • Sakura, Chiba, Japón, 285-8741
        • Toho University Sakura Medical Center
      • Urayasu, Chiba, Japón, 279-0021
        • Juntendo University Urayasu Hospital
    • Hyōgo
      • Takarazuka, Hyōgo, Japón, 665-0827
        • Takarazuka City Hospital
    • Ibaraki
      • Inashiki-gun, Ibaraki, Japón, 300-0395
        • Tokyo Medical University Ibaraki Medical Center
    • Nara
      • Ikoma, Nara, Japón, 630-0293
        • Kindai University Nara Hospital
    • Osaka
      • Habikino, Osaka, Japón, 583-8588
        • Osaka Habikino Medical Center
    • Shizuoka
      • Hamamatsu, Shizuoka, Japón, 431-3192
        • Hamamatsu University Hospital
    • Tokyo
      • Bunkyo-ku, Tokyo, Japón, 113-8519
        • Institute of Science Tokyo Hospital
    • Yamaguchi
      • Ube, Yamaguchi, Japón, 755-8505
        • Yamaguchi University Hospital
    • Chihuahua
      • Chihuahua City, Chihuahua, México, 31238
        • Servicios Hospitalarios de Mexico S.A. DE C.V.
    • Mexico City
      • Mexico City, Mexico City, México, 06700
        • Trials in Medicine
    • Michoacán
      • Morelia, Michoacán, México, 58249
        • Clinica de Enfermedades Cronicas y Procedimientos Especiales, SC
    • Nuevo León
      • Monterrey, Nuevo León, México, 64060
        • Cri Centro Regiomontano de Investigacion
    • Veracruz
      • Veracruz, Veracruz, México, 91900
        • Arké SMO S.A de C.V
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polonia, 85-650
        • Clinica Dermatoestetica Prywatny Gabinet Dermatologiczny I Alergologiczny Prof.Dr Hab.Med. Barbara Z
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polonia, 30-002
        • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka
      • Krakow, Lesser Poland Voivodeship, Polonia, 31-501
        • Krakowskie Centrum Medyczne
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polonia, 02-677
        • ETG Warszawa
      • Warsaw, Masovian Voivodeship, Polonia, 02-953
        • Klinika Ambroziak Dermatologia
      • Warsaw, Masovian Voivodeship, Polonia, 02-962
        • Royalderm Agnieszka Nawrocka
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Polonia, 15-375
        • Specderm Poznanska sp.j.
      • Bialystok, Podlaskie Voivodeship, Polonia, 15-879
        • ClinicMed Daniluk, Nowak Spółka komandytowa
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Polonia, 40-611
        • Centrum Medyczne Angelius Provita
    • West Pomeranian Voivodeship
      • Szczecin, West Pomeranian Voivodeship, Polonia, 71-500
        • Twoja Przychodnia SCM
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Polonia, 90-265
        • "DERMED" Centrum Medyczne Sp. z o.o.
      • Shanghai, Porcelana, 200080
        • Shanghai General Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100730
        • Peking Union Medical College Hospital
      • Beijing, Beijing Municipality, Porcelana, 100050
        • Beijing Friendship Hospital Affiliate of Capital University
    • Fujian
      • Fuzhou, Fujian, Porcelana, 350005
        • The First Affiliated Hospital Of Fujian Medical University
    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510180
        • Guangzhou First People's Hospital
      • Guangzhou, Guangdong, Porcelana, 510091
        • Dermatology Hospital of Southern Medical University
    • Guizhou
      • Guiyang, Guizhou, Porcelana, 550004
        • The Affiliated Hospital of Guizhou Medical University
    • Hebei
      • Shijiazhuang, Hebei, Porcelana, 050030
        • The First Hospital of Hebei Medical University
    • Henan
      • Nanyang, Henan, Porcelana, 473000
        • NanYang First people's hospital
    • Hubei
      • Wuhan, Hubei, Porcelana, 430022
        • The First Hospital of Wuhan
    • Hunan
      • Changsha, Hunan, Porcelana, 410011
        • The Second Xiangya Hospital of Central South University
    • Inner Mongolia
      • Baotou, Inner Mongolia, Porcelana, 014010
        • The First Affiliated Hospital of Baotou Medical College
    • Jiangsu
      • Nanjing, Jiangsu, Porcelana, 210029
        • Jiangsu Province Hospital
    • Jilin
      • Changchun, Jilin, Porcelana, 130021
        • The First Hospital of Jilin University
    • Shaanxi
      • Xi'an, Shaanxi, Porcelana, 710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 200040
        • Huashan Hospital, Fudan University
    • Sichuan
      • Chengdu, Sichuan, Porcelana, 610041
        • West China Hospital, Sichuan University
      • Chengdu, Sichuan, Porcelana, 610017
        • Chengdu second people's hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Porcelana, 300052
        • Tianjin Medical University General Hospital
    • Yunnan
      • Kunming, Yunnan, Porcelana, 650032
        • First Affiliated Hospital of Kunming Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, Porcelana, 310009
        • Hangzhou Third Hospital
      • Hangzhou, Zhejiang, Porcelana, 310016
        • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
      • San Juan, Puerto Rico, 00909
        • Clinical Research Puerto Rico
      • San Juan, Puerto Rico, 00909
        • Cardiovascular Radiology Institute
      • San Juan, Puerto Rico, 00927
        • Centro de Audiología y Balance
    • England
      • Isleworth, England, Reino Unido, TW7 6AF
        • West Middlesex University Hospital
    • HAMPSHIRE
      • Southampton, HAMPSHIRE, Reino Unido, SO16 6YD
        • Southampton General Hospital
    • London, CITY of
      • London, London, CITY of, Reino Unido, SE1 9RT
        • Guy's & St Thomas' NHS Foundation Trust
      • Kaohsiung City, Taiwán, 80756
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Kaohsiung City, Taiwán, 833401
        • Kaohsiung Chang Gung Memorial Hospital
      • Taipei, Taiwán, 100225
        • National Taiwan University Hospital
    • TAOYUAN
      • Taoyuan, TAOYUAN, Taiwán, 333
        • Chang Gung Medical Foundation-Linkou Branch
    • Taipei
      • Taipei, Taipei, Taiwán, 11217
        • Taipei Veterans General Hospital
    • Ankara
      • Ankara, Ankara, Turquía (Türkiye), 06560
        • Gazi University Health Research and Application Center Gazi Hospital
    • Istanbul
      • Istanbul, Istanbul, Turquía (Türkiye), 34093
        • Bezmialem Vakf Üniversitesi

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Participants aged 18 years (or the minimum age of consent in accordance with local regulations) or older (no upper age limit) at Screening.

    • Meeting reproductive criteria for female participants.

    Disease Characteristics:

  2. Eligible participants must have at both Screening and BL:

    • A clinical diagnosis of nonsegmental vitiligo for at least 3 months; and
    • BSA involvement 4% to 60% inclusive, excluding involvements at palms of the hands, soles of the feet, or dorsal aspect of the feet and
    • BSA ≥0.5% involvement on the face. Face is defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. Face will not include scalp, ears, neck, or surface area of the lips, but will include the nose and the eyelids; and
    • F-VASI ≥0.5 and T-VASI ≥3; and
    • Either active or stable nonsegmental vitiligo at Screening and BL visits. All participants who do not have the features of active vitiligo (defined below) will be classified as having stable disease.

    Active vitiligo is defined as:

    Participants will be classified as having active vitiligo based on the presence of at least one active lesion at BL defined as one of the following:

    • New/extending lesions(s) in the 3 months prior to Screening visit (confirmed by photographs or medical record);
    • Confetti-like lesion(s); Confetti-like depigmentation is characterized by the presence of numerous 1-mm to 5-mm depigmented macules in clusters;
    • Trichrome lesion(s); Trichrome lesions have a hypopigmented zone of varying width between normal and completely depigmented skin, resulting in 3 different hues of skin;
    • Koebner phenomenon/phenomena (excluding Type 1 [history based on isomorphic reaction]). The Koebner phenomenon manifests as depigmentation at sites of trauma, usually in a linear arrangement.

    Stable vitiligo is defined as:

    • Participants will be classified as having stable vitiligo based on an absence of signs of active disease. All participants who do not have the features of active vitiligo (defined above) will be classified as having stable disease.

    Eligibility is determined at Screening and Baseline based on the resulting scores from the local in-person reads of F-VASI, T-VASI, and BSA.

  3. Additional inclusion criteria are:

    • If receiving concomitant medications for any reason other than vitiligo, participant must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1. Participant must be willing to stay on a stable regimen during the duration of the study.
    • Must agree to stop all other treatments for vitiligo from Screening through the final follow-up visit.

Exclusion Criteria:

Medical Conditions:

  1. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    • Any psychiatric condition including recent or active suicidal ideation or behavior that meets defined criteria.

  2. Medical conditions pertaining to vitiligo and other diseases/conditions affecting the skin:

    • Participants that have other types of vitiligo that do not meet criteria for active or stable vitiligo as noted in inclusion criteria (including but not limited to segmental vitiligo and mixed vitiligo).
    • Currently have active forms of other hypopigmentation (including but not limited to Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation [melanoma and mycosis fungoides], post-inflammatory hypopigmentation, pityriasis alba [minor manifestation of atopic dermatitis], senile leukoderma [age-related depigmentation], chemical/drug-induced leukoderma, ataxia telangiectasia, tuberous sclerosis, melasma, and congenital hypopigmentation disorder including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, dyschromatosis symmetrica hereditarian, xeroderma pigmentosum, and nevus depigmentosus). NOTE: Coexistence of halo nevus/nevi (also known as Sutton nevus/nevi) is permitted.
    • Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions (for example, but not limited to morphea, discoid lupus, leprosy, syphilis, psoriasis, seborrheic dermatitis) at the time of the Screening or BL Visit that in the opinion of the investigator would interfere with evaluation of vitiligo or response to treatment.
    • Leukotrichia in more than 33% of the face surface area affected with vitiligo lesions or leukotrichia in more than 33% of the total body surface area affected with vitiligo lesions.
    • Have a superficial skin infection within 2 weeks prior to first dose on Day 1. NOTE: participants may be rescreened after the infection resolves.
  3. General Infection History:

    • Have a history of systemic infection requiring hospitalization, parenteral antimicrobial, antiviral (including biologic treatment), antiparasitic, antiprotozoal, or antifungal therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 1.
    • Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1. NOTE: participants may be rescreened after the infection resolves.
    • Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium tuberculosis.
  4. Specific Viral Infection History:

    • History (single episode) of disseminated HZ or disseminated herpes simplex or recurrent (more than one episode of) localized, dermatomal HZ.
    • Infected with HBV or HCV: all participants will undergo screening for HBV and HBC for eligibility.
    • Participants who are positive for HCVAb and HCV RNA will not be eligible for this study.
    • Have a known immunodeficiency disorder (including positive serology for HIV at screening) or a first-degree relative with a hereditary immunodeficiency.
  5. Other Medical Conditions:

    • Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (eg, untreated hypovitaminosis D or hypothyroidism), pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator or Pfizer (or designee), the participant is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and lifestyle requirements.
    • History of severe allergic or anaphylactoid reaction to any kinase inhibitor or a known allergy/hypersensitivity to any component (including excipients) of the study intervention.
    • Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered current, fluctuating, or progressive.
    • Have a history of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.
    • Abnormal findings on the Screening chest imaging (eg, chest x-ray). Chest imaging may be performed up to 12 weeks prior to screening. Documentation of the official reading must be located and available in the source documentation.
    • Long QT Syndrome, a family history of Long QT Syndrome, or a history of TdP.
    • Have any malignancies or have a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
    • Significant trauma or major surgery within 1 month of the first dose of study drug or considered in imminent need for surgery or with elective surgery scheduled to occur during the study.

    Prior/Concomitant Therapy:

  6. Have received any of the prohibited treatment regimens specified.

    Prior/Concurrent Clinical Study Experience:

  7. Previous administration with an investigational drug or vaccine that do not affect vitiligo within 4 weeks of Day 1 [Baseline] or within 5 half-lives, whichever is longer.

    Diagnostic Assessments:

    Any of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and, if deemed necessary, confirmed by a single repeat:

  8. Renal impairment

  9. Hepatic dysfunction

  10. Other laboratory abnormalities

  11. Standard 12-lead ECG that demonstrates clinically relevant abnormalities

    Other Exclusion Criteria:

  12. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm 1- Ritlecitinib 100 milligrams (mg)

Randomized to Ritlecitinib 100 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.

100mg Capsule

50mg Capsule

Experimental: Arm 2- Ritlecitinib 50mg

Randomized to Ritlecitinib 50 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.

100mg Capsule

50mg Capsule

Comparador de placebos: Arm 3- Placebo

Randomized to Placebo QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.

Matching capsule

Experimental: Arm 4- Ritlecitinib 100mg

Non-randomized open-label Ritlecitinib 100mg QD for 52 weeks.

100mg Capsule

50mg Capsule

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidencia de anomalías de laboratorio clínicamente significativas.
Periodo de tiempo: Línea de base hasta las 108 semanas
Línea de base hasta las 108 semanas
US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and Total body Vitiligo Area Scoring Index 50 (T-VASI50) at Week 52
Periodo de tiempo: 52 Weeks

Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) and T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)

52 Weeks
Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52
Periodo de tiempo: 52 Weeks

Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline).

52 Weeks
Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) leading to discontinuation.
Periodo de tiempo: Baseline through 108 weeks

To evaluate the safety and tolerability of ritlecitinib in adult participants with non segmental vitiligo

Baseline through 108 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Es hora de rescatar el uso de medicamentos
Periodo de tiempo: Línea de base hasta la semana 104
Línea de base hasta la semana 104
Response based on F-VASI75 at 24 and 36 weeks
Periodo de tiempo: 24 and 36 Weeks

Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline.

24 and 36 Weeks
US-Only: Response based on T-VASI50 at 24 and 36 weeks
Periodo de tiempo: 24 and 36 weeks

Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline).

24 and 36 weeks
Global (Other than US):Patient Global Impression of Severity-Face (PGIS-F)
Periodo de tiempo: Week 24, 36 and week 52

To assess the effect of ritlecitinib compared to placebo on the PGIS-F at Week 24, 36 and 52

Week 24, 36 and week 52
Global (Other than US): Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)
Periodo de tiempo: Week 24, 36 and week 52

To assess the effect of ritlecitinib compared to placebo on the PGIS-V at Week 24, 36 and 52

Week 24, 36 and week 52
Global (Other Than US): Response based on T-VASI50 at Week 24, 36 and 52
Periodo de tiempo: Week 24, 36 and 52

Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline).

Week 24, 36 and 52
Patient Global Impression of Change-Face (PGIC-F)
Periodo de tiempo: Week 36 and week 52

To assess the effect of ritlecitinib compared to placebo on the PGIC-F at Weeks 36 and 52.

Week 36 and week 52
Patient Global Impression of Change- Overall vitiligo(PGIC-V)
Periodo de tiempo: Week 36 and week 52

To assess the effect of ritlecitinib compared to placebo on the PGIC-V at Weeks 36 and 52.

Week 36 and week 52
Change from baseline in Dermatology Life Quality Index (DLQI)
Periodo de tiempo: Week 52

To evaluate the change from baseline in DLQI at week 52

Week 52
Proportion of participants achieving disease stabilization
Periodo de tiempo: Baseline through week 104

The difference in the proportion of participants with stable disease at all timepoints in participants with non segmental vitiligo treated with ritlecitinib 50 mg QD and 100mg compared to placebo

Baseline through week 104
Response based on T-VASI50
Periodo de tiempo: Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.

Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)

Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
Response based on F-VASI75
Periodo de tiempo: Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.

Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline)

Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
Response based on T-VASI75
Periodo de tiempo: Baseline through week 4, week 8, week 12, week 24, week 36, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.

Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline)

Baseline through week 4, week 8, week 12, week 24, week 36, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
Global (Other than US): Response based on T-VASI75
Periodo de tiempo: Baseline through week 52

Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline)

Baseline through week 52
Proportion of participants with sustained improvement in T-VASI
Periodo de tiempo: Week 36 through week 52

Defined as maintenance of ≥T-VASI50 from Week 36 to Week 52

Week 36 through week 52
Proportion of participants with sustained improvement in F-VASI
Periodo de tiempo: Week 36 through week 52

Defined as maintenance of ≥F-VASI75 from Week 36 to 52

Week 36 through week 52
US-Only: Percentage change from baseline (% CFB) in F-VASI at Weeks 24, 36 and 52
Periodo de tiempo: Weeks 24, 36 and 52

To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in F-VASI at Weeks 24, 36 and 52

Weeks 24, 36 and 52
US-Only: % CFB in T-VASI at weeks 24, 36 and 52
Periodo de tiempo: Weeks 24, 36 and 52

To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in T-VASI at Weeks 24,36 and 52

Weeks 24, 36 and 52
Response based on T-VASI90
Periodo de tiempo: Baseline through week 52

Proportion of participants achieving T-VASI90 (defined as at least 90% improvement in T-VASI from Baseline)

Baseline through week 52
Response based on T-VASI100
Periodo de tiempo: Baseline through week 52

Proportion of participants achieving T-VASI90 (defined as at least 100% improvement in T-VASI from Baseline)

Baseline through week 52
Response based on F-VASI50
Periodo de tiempo: Baseline through week 104

Proportion of participants achieving F-VASI50 (defined as at least 50% improvement in F-VASI from Baseline).

Baseline through week 104
Change from baseline in the Hospital Anxiety and Depression Scale (HADS)
Periodo de tiempo: Week 52

To assess the effect of ritlecitinib compared to placebo on depression and anxiety subscales of the HADS at week 52

Week 52
The proportion of patients achieving absence of depression on HADS depression subscale
Periodo de tiempo: Week 52

Response based on a 'normal' subscale score indicative of an absence of depression (in participants with baseline HADS subscale scores indicative of depression)

Week 52
The proportion of patients achieving absence of anxiety on HADS anxiety subscale
Periodo de tiempo: Week 52

Response based on a 'normal' subscale score indicative of an absence of anxiety (in participants with baseline HADS subscale scores indicative of anxiety)

Week 52
US-Only: Patient Global Impression of Severity-Face (PGIS-F)
Periodo de tiempo: Week 52

To assess the effect of ritlecitinib compared to placebo on the PGIS-F at 52

Week 52
US-Only: Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)
Periodo de tiempo: Week 52

To assess the effect of ritlecitinib compared to placebo on the PGIS-V at 52

Week 52
% CFB in F-VASI at Week 4, 8, 12, 48, 56, 60, 64, 76, 88 and 104.
Periodo de tiempo: Baseline through week 104

To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in F-VASI at all time points

Baseline through week 104
% CFB in T-VASI at Week 4, 8, 12, 48, 56, 60, 64, 76, 88 and 104.
Periodo de tiempo: Baseline through week 104

To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in T-VASI at all time points

Baseline through week 104

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Pfizer CT.gov Call Center, Pfizer

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

8 de noviembre de 2023

Finalización primaria (Estimado)

30 de julio de 2027

Finalización del estudio (Estimado)

30 de julio de 2027

Fechas de registro del estudio

Enviado por primera vez

2 de octubre de 2023

Primero enviado que cumplió con los criterios de control de calidad

2 de octubre de 2023

Publicado por primera vez (Actual)

10 de octubre de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • B7981080
  • 2022-502518-98-00 (Identificador de registro: CTIS (EU))

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir